ADC Therapeutics SA vs Kura Oncology
ADC Therapeutics SA is the larger business, with $81.4m of revenue in fiscal 2025 against $67.5m for Kura Oncology (1.2 times as much). Kura Oncology grew faster (25.2% against 14.9%). ADC Therapeutics SA kept more of each dollar of sales as profit: a net margin of -175.3% against -412.9%.
| Latest fiscal year | ADC Therapeutics SAADCT, 2025 | Kura OncologyKURA, 2025 |
|---|---|---|
| Revenue | $81.4m | $67.5m |
| Revenue growth | 14.9% | 25.2% |
| Net income | −$143m | −$279m |
| Operating margin | -149.3% | -449.9% |
| Net margin | -175.3% | -412.9% |
| Return on equity | — | -94.8% |
| Free cash flow | −$141m | −$70.7m |
| Cash | $261m | $149m |
| Total debt | $116m | $9.7m |
| Debt to equity | — | 5.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 188 | 260 |
| Market value | $198m | $879m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 6 sales | 2 buys, 39 sales |